Proper Dosage of Ketamine in Intravenous Regional Anesthesia

Proper Dosage of Intravenous Ketamine When Used as an Adjuvant to Lidocaine in Intravenous Regional Anesthesia (IVRA).

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00221871

Enrollment

Unknown

Registered

2005-09-22

Start date

2004-01-31

Completion date

2005-01-31

Last updated

2006-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain.

Brief summary

Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.

Interventions

DRUGDifferent dosages of Ketamine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Age: 18-70 2. Weight: 50-100 kg 3. ASA: I, II, III 4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

Exclusion criteria

1. Contraindication to IVRA such as sickle cell disease. 2. Any known hypersensitivity reaction to Ketamine. 3. History of chronic pain or regular medication with analgesics. 4. History of opioid dependence. 5. Drug of alcohol abuse. 6. Psychiatric disorder. 7. Allergy to acetaminophen or codeine

Countries

Canada

Contacts

Primary ContactColin McCartney, MD

colin.mccartney@uhn.on.ca(416)603-5118

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026